Gilead's Epclusa Approved As First Pan-Genotypic HCV Therapy
Fixed-dose combo of sofosbuvir and velpatasvir is approved to treat genotypes 1-6 and be the first ribavirin-free regimen for genotypes 2 and 3 of the virus.
You may also be interested in...
Bangladesh's HCV market report card currently reads along these lines: generic versions of Sovaldi and Daklinza have made significant gains leaving interferon by the wayside, while generic Harvoni has had a quiet run. But, the arrival of cut-price Epclusa generics could bring change, besides putting the spotlight on the growing prowess of the South Asian nation's pharmaceutical industry.
GSK, Bayer, Celgene, Amgen, AstraZeneca, Bristol-Myers Squibb, Sanofi, Merck & Co and AbbVie are among the pharma companies due to report second-quarter results imminently. As the financial reporting season moves into a second week, Scrip takes a look at the key things to watch for.
Nexavar compulsory license holder Natco Pharma is counted among the leading players in the Indian oncology market and now looks to be aiming for an encore in the hepatitis C segment. Natco vice chair and CEO Rajeev Nannapaneni talks to Scrip of the large patient numbers on HCV therapy and outlines a potential market "split" in certain rest of the world (RoW) territories with the arrival of Gilead's Epclusa.